Connect Other Current Liab vs Inventory Analysis

CNTB Stock

USD 1.78 0.06 3.49%

Connect Biopharma financial indicator trend analysis is way more than just evaluating Connect Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Connect Biopharma is a good investment. Please check the relationship between Connect Biopharma Other Current Liab and its Inventory accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

Other Current Liab vs Inventory

Other Current Liab vs Inventory Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Connect Biopharma Other Current Liab account and Inventory. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Connect Biopharma's Other Current Liab and Inventory is -0.4. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Inventory in the same time period over historical financial statements of Connect Biopharma Holdings, assuming nothing else is changed. The correlation between historical values of Connect Biopharma's Other Current Liab and Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Connect Biopharma Holdings are associated (or correlated) with its Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory has no effect on the direction of Other Current Liab i.e., Connect Biopharma's Other Current Liab and Inventory go up and down completely randomly.

Correlation Coefficient

-0.4

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Other Current Liab

Inventory

Most indicators from Connect Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Connect Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

At present, Connect Biopharma's Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.27, whereas Tax Provision is forecasted to decline to about 114 K.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	4.1M	6.9M	988K	938.6K
Total Operating Expenses	621.5M	785.2M	64.8M	61.6M

Reconciled Depreciation Total Operating Expenses

Connect Biopharma fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Net Tangible Assets	Retained Earnings	Accounts Payable	Other Assets	Net Receivables	Other Stockholder Equity	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Inventory	Other Current Assets
Other Current Liab		0.98	0.49	-0.94	0.97	0.52	0.77	0.72	0.91	0.91	0.58	0.95	0.48	-0.04	0.96	-0.85	0.85	0.93	0.45	0.95	-0.21	0.46	-0.22	0.48	-0.4	-0.43
Total Current Liabilities	0.98		0.59	-0.98	0.99	0.36	0.7	0.66	0.83	0.91	0.65	0.88	0.57	-0.14	0.91	-0.74	0.74	0.96	0.29	0.88	-0.23	0.58	-0.35	0.57	-0.52	-0.53
Net Tangible Assets	0.49	0.59		-0.57	0.5	-0.3	0.38	0.55	0.14	0.35	0.97	0.22	0.16	0.09	0.47	-0.11	0.11	0.48	-0.28	0.21	-0.59	0.33	-0.84	0.16	-0.94	-0.82
Retained Earnings	-0.94	-0.98	-0.57		-0.97	-0.26	-0.55	-0.51	-0.78	-0.9	-0.65	-0.84	-0.7	0.33	-0.83	0.64	-0.64	-0.97	-0.15	-0.84	0.21	-0.71	0.31	-0.7	0.58	0.6
Accounts Payable	0.97	0.99	0.5	-0.97		0.36	0.67	0.61	0.85	0.95	0.56	0.89	0.64	-0.2	0.9	-0.73	0.73	0.97	0.32	0.89	-0.14	0.62	-0.31	0.64	-0.45	-0.45
Other Assets	0.52	0.36	-0.3	-0.26	0.36		0.63	0.52	0.74	0.36	-0.15	0.71	-0.17	0.36	0.57	-0.86	0.86	0.27	0.88	0.71	0.03	-0.31	0.55	-0.17	0.44	0.3
Net Receivables	0.77	0.7	0.38	-0.55	0.67	0.63		0.96	0.8	0.68	0.39	0.79	-0.05	0.57	0.92	-0.88	0.88	0.6	0.78	0.79	-0.19	-0.1	-0.29	-0.05	-0.09	-0.03
Other Stockholder Equity	0.72	0.66	0.55	-0.51	0.61	0.52	0.96		0.66	0.55	0.57	0.68	-0.18	0.64	0.86	-0.78	0.77	0.51	0.63	0.67	-0.39	-0.17	-0.4	-0.18	-0.27	-0.19
Total Current Assets	0.91	0.83	0.14	-0.78	0.85	0.74	0.8	0.66		0.89	0.23	0.99	0.4	0.04	0.92	-0.96	0.96	0.83	0.72	0.99	0.02	0.3	0.06	0.4	-0.01	-0.06
Common Stock	0.91	0.91	0.35	-0.9	0.95	0.36	0.68	0.55	0.89		0.36	0.9	0.69	-0.2	0.89	-0.74	0.74	0.97	0.42	0.9	0.05	0.63	-0.28	0.69	-0.26	-0.24
Property Plant Equipment	0.58	0.65	0.97	-0.65	0.56	-0.15	0.39	0.57	0.23	0.36		0.31	0.16	0.04	0.52	-0.22	0.22	0.51	-0.24	0.31	-0.65	0.33	-0.67	0.16	-0.94	-0.88
Total Assets	0.95	0.88	0.22	-0.84	0.89	0.71	0.79	0.68	0.99	0.9	0.31		0.44	0.0	0.94	-0.95	0.95	0.87	0.66	1.0	-0.04	0.35	0.01	0.44	-0.1	-0.15
Short Long Term Debt Total	0.48	0.57	0.16	-0.7	0.64	-0.17	-0.05	-0.18	0.4	0.69	0.16	0.44		-0.83	0.31	-0.13	0.13	0.75	-0.23	0.44	0.22	0.98	-0.15	1.0	-0.32	-0.35
Total Stockholder Equity	-0.04	-0.14	0.09	0.33	-0.2	0.36	0.57	0.64	0.04	-0.2	0.04	0.0	-0.83		0.2	-0.29	0.28	-0.31	0.57	-0.01	-0.22	-0.83	-0.16	-0.83	0.22	0.32
Property Plant And Equipment Net	0.96	0.91	0.47	-0.83	0.9	0.57	0.92	0.86	0.92	0.89	0.52	0.94	0.31	0.2		-0.9	0.9	0.86	0.61	0.94	-0.19	0.27	-0.29	0.31	-0.29	-0.27
Net Debt	-0.85	-0.74	-0.11	0.64	-0.73	-0.86	-0.88	-0.78	-0.96	-0.74	-0.22	-0.95	-0.13	-0.29	-0.9		-1.0	-0.67	-0.83	-0.94	0.08	-0.02	-0.12	-0.13	-0.07	-0.01
Cash	0.85	0.74	0.11	-0.64	0.73	0.86	0.88	0.77	0.96	0.74	0.22	0.95	0.13	0.28	0.9	-1.0		0.67	0.83	0.95	-0.07	0.02	0.13	0.13	0.07	0.01
Non Current Assets Total	0.93	0.96	0.48	-0.97	0.97	0.27	0.6	0.51	0.83	0.97	0.51	0.87	0.75	-0.31	0.86	-0.67	0.67		0.25	0.87	-0.07	0.73	-0.32	0.75	-0.44	-0.44
Non Currrent Assets Other	0.45	0.29	-0.28	-0.15	0.32	0.88	0.78	0.63	0.72	0.42	-0.24	0.66	-0.23	0.57	0.61	-0.83	0.83	0.25		0.65	0.16	-0.39	0.29	-0.23	0.54	0.52
Cash And Short Term Investments	0.95	0.88	0.21	-0.84	0.89	0.71	0.79	0.67	0.99	0.9	0.31	1.0	0.44	-0.01	0.94	-0.94	0.95	0.87	0.65		-0.04	0.35	0.02	0.44	-0.1	-0.16
Common Stock Shares Outstanding	-0.21	-0.23	-0.59	0.21	-0.14	0.03	-0.19	-0.39	0.02	0.05	-0.65	-0.04	0.22	-0.22	-0.19	0.08	-0.07	-0.07	0.16	-0.04		0.09	0.31	0.22	0.54	0.41
Short Term Investments	0.46	0.58	0.33	-0.71	0.62	-0.31	-0.1	-0.17	0.3	0.63	0.33	0.35	0.98	-0.83	0.27	-0.02	0.02	0.73	-0.39	0.35	0.09		-0.29	0.98	-0.51	-0.52
Non Current Liabilities Total	-0.22	-0.35	-0.84	0.31	-0.31	0.55	-0.29	-0.4	0.06	-0.28	-0.67	0.01	-0.15	-0.16	-0.29	-0.12	0.13	-0.32	0.29	0.02	0.31	-0.29		-0.15	0.72	0.49
Capital Lease Obligations	0.48	0.57	0.16	-0.7	0.64	-0.17	-0.05	-0.18	0.4	0.69	0.16	0.44	1.0	-0.83	0.31	-0.13	0.13	0.75	-0.23	0.44	0.22	0.98	-0.15		-0.32	-0.35
Inventory	-0.4	-0.52	-0.94	0.58	-0.45	0.44	-0.09	-0.27	-0.01	-0.26	-0.94	-0.1	-0.32	0.22	-0.29	-0.07	0.07	-0.44	0.54	-0.1	0.54	-0.51	0.72	-0.32		0.94
Other Current Assets	-0.43	-0.53	-0.82	0.6	-0.45	0.3	-0.03	-0.19	-0.06	-0.24	-0.88	-0.15	-0.35	0.32	-0.27	-0.01	0.01	-0.44	0.52	-0.16	0.41	-0.52	0.49	-0.35	0.94

Click cells to compare fundamentals

Connect Biopharma Account Relationship Matchups

Connect Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	4.2M	12.8M	32.8M	24.4M	3.0M	2.8M
Total Current Liabilities	27.4M	38.0M	114.7M	108.8M	24.3M	23.1M
Retained Earnings	(292.1M)	(1.1B)	(2.4B)	(3.2B)	(539.3M)	(566.3M)
Accounts Payable	22.8M	24.6M	81.2M	83.1M	7.7M	7.3M
Net Receivables	1.2M	1.7M	47.3M	1.6M	178K	169.1K
Other Stockholder Equity	42.5M	48.1M	4.2B	(71.2M)	648.3M	876.5M
Total Current Assets	362.8M	1.1B	1.8B	1.1B	121.0M	114.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock:

How To Invest In Connect

Details

Is Connect Stock a good investment?

Details

What is Connect Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Connect Stock analysis

When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.

	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules

Is Connect Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.08)

Return On Assets

(0.27)

Return On Equity

(0.46)

The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Connect Other Current Liab vs Inventory Analysis

Other Current Liab vs Inventory

Other Current Liab vs Inventory Correlation Analysis

Correlation Coefficient

Other Current Liab

Inventory

Connect Biopharma fundamental ratios Correlations

Connect Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Connect Biopharma fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Connect Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Accounts Payable	+ 0.99	Total Current Liabilities
Total Assets	+ 0.99	Total Current Assets
Cash And Short Term Investments	+ 0.99	Total Current Assets
Total Current Liabilities	+ 0.98	Other Current Liab

Cash	- 1.0	Net Debt
Retained Earnings	- 0.98	Total Current Liabilities
Non Current Assets Total	- 0.97	Retained Earnings
Accounts Payable	- 0.97	Retained Earnings
Net Debt	- 0.96	Total Current Assets
Net Debt	- 0.95	Total Assets